Howard Li, M.D.
Research program member: Developmental Therapeutics
1220 E. Broad St.
Richmond, VA 23298
Associate Professor, Internal Medicine, School of Medicine
Associate Professor, Medicine, Hunter Holmes McGuire VA Medical Center
MD, Vanderbilt University (2002)
My laboratory focuses on various pathways that regulate immune responses during lung cancer progression. These include prostacyclin, which is a prostaglandin derived from arachidonic acid that is a potent vasodilator and inhibitor of platelet aggregation. In preclinical mouse models, prostacyclin inhibits lung cancer growth by activating anti-tumor T cell responses. One goal of my laboratory's research is to define the cellular and molecular mechanisms whereby prostacyclin regulates anti-tumor immunity. My laboratory also studies the role of immune checkpoints in the progression of premalignant lung lesions to lung cancer, and whether immune checkpoint inhibitors are pharmacologic agents that may prevent the development of lung cancer in high-risk individuals. More recently, my laboratory has started a project that focuses on the role of microRNAs in regulating responses of lung cancer to immune checkpoint inhibition.
Animal models,Immunotherapy,Inflammation,Metastasis,Tumor microenvironment